Conexeu Sciences CEO Discusses Tissue Regeneration Market Opportunities
In a fireside chat with IPO Edge, Conexeu Sciences (Nasdaq: CNXU) CEO Miles Harrison outlined the company's strategy in developing tissue-regeneration technology for multiple medical applications. The discussion highlighted how rising use of weight-loss drugs like GLP-1 is increasing demand for treatments to restore facial and body volume lost through rapid weight loss. Harrison emphasized Conexeu’s focus on a single, scalable platform designed as an alternative to traditional fillers and implants across wound care, aesthetics, oral health, veterinary medicine, and reconstruction. The company plans to submit its first FDA 510(k) application in early 2027 for initial product approval. Key upcoming milestones include regulatory progress, data publications, expansion into dental and veterinary markets, and development of a bioresorbable scaffold as an alternative to silicone breast implants.
Topics: biotech FDA regulatory process GLP-1 drugs IPO Edge tissue regeneration